A5060655239- Hepatocellular Carcinoma Treatment and Prognosis
- CAR-T cell therapy research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Autophagy in Disease and Therapy
- Liver Disease Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Cancer Mechanisms and Therapy
- Cancer-related molecular mechanisms research
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Diagnosis and Treatment
- Liver physiology and pathology
- PI3K/AKT/mTOR signaling in cancer
- Thyroid Cancer Diagnosis and Treatment
- Ubiquitin and proteasome pathways
- Cancer, Lipids, and Metabolism
- Medical Imaging and Pathology Studies
- Congenital Heart Disease Studies
- MicroRNA in disease regulation
- Genetic and Kidney Cyst Diseases
- Gallbladder and Bile Duct Disorders
- RNA modifications and cancer
- Neuroblastoma Research and Treatments
- Peptidase Inhibition and Analysis
Renji Hospital
2016-2025
Shanghai East Hospital
2025
Zhejiang Chinese Medical University
2025
Shanghai Jiao Tong University
2015-2024
Zhengzhou Children's Hospital
2018-2024
Zhengzhou University
2018-2024
State Key Laboratory of Oncogene and Related Genes
2021-2024
Shanghai Cancer Institute
2021-2024
Nanjing University of Posts and Telecommunications
2024
Harbin Medical University
2013-2023
Nearly every extracellular ligand that has been found to play a role in regulating bone biology acts, at least part, through MAPK pathways. Nevertheless, much remains be learned about the contribution of MAPKs osteoblast vivo. Here we report p38 pathway is required for normal skeletogenesis mice, as mice with deletion any member–encoding genes kinase 3 (Mkk3), Mkk6, p38a, or p38b displayed profoundly reduced mass secondary defective differentiation. Among (MAP3K) family, identified...
Sorafenib is the standard first-line systemic drug for advanced hepatocellular carcinoma (HCC), but acquired resistance to sorafenib results in limited benefits. Activation of Akt thought be responsible mediating sorafenib. The present study aims examine underlying mechanism and seek potential strategies reverse this resistance. Two sorafenib-resistant HCC cell lines, which had been established from human HepG2 Huh7 cells, were refractory sorafenib-induced growth inhibition apoptosis vitro...
Our preclinical studies demonstrated the potential of chimeric antigen receptor (CAR)-glypican-3 (GPC3) T-cell therapy for hepatocellular carcinoma (HCC). We report herein first published results CAR-GPC3 HCC.In two prospective phase I studies, adult patients with advanced GPC3+ HCC (Child-Pugh A) received autologous following cyclophosphamide- and fludarabine-induced lymphodepletion. The primary objective was to assess treatment's safety. Adverse events were graded using Common Terminology...
Mutations in the RNA binding protein FUS cause amyotrophic lateral sclerosis (ALS), a fatal adult motor neuron disease. Decreased expression of SMN causes childhood disorder spinal muscular atrophy (SMA). The complex localizes both cytoplasm and nuclear Gems, loss Gems is cellular hallmark fibroblasts patients with SMA. Here, we report that associates complex, mediated by U1 snRNP direct interactions between SMN. Functionally, show required for Gem formation HeLa cells, containing severe...
// Changjun He 1, 2, 3 , Xuesong Dong Bo Zhai Xian Jiang Deli 2 Baoxin Li Hongchi Shidong Xu 1 Xueying Sun Department of Surgery, the Affiliated Cancer Hospital Harbin Medical University, Harbin, China Pharmacology, State-Province Key Laboratories Biomedicine-Pharmaceutics China, The Hepatosplenic Surgery Center, General First Correspondence to: Sun, e-mail: kevsun88@hotmail.com k.sun@auckland.ac.nz Xu, xusd163@163.com Keywords: sorafenib, hepatocellular carcinoma, miR-21, phosphatase and...
Acquired resistance to sorafenib greatly limits its therapeutic efficiency in the treatment of hepatocellular carcinoma (HCC). Increasing evidence indicates that long noncoding RNAs (lncRNAs) play important roles anti-cancer drugs. The present study aims explore involvement lncRNA SNHG1 (small nucleolar RNA host gene 1) and how is associated with overexpressed microRNA-21 (miR-21) activated Akt pathway, which have been demonstrated mediate this HCC cells.Sorafenib-resistant (SR-HCC) cells...
Sorafenib, the unique drug as first-line treatment for advanced hepatocellular carcinoma (HCC), has opened a window of hope after searching effective agents to combat HCC decades.However, overall outcomes are far from satisfactory.One explanations is genetic heterogeneity HCC, which led identifying predictive biomarkers primary resistance sorafenib, and then applying concept personalized medicine, or seeking therapeutic strategies such combining sorafenib with other anticancer agents.Some...
The study of pathophysiological mechanisms in human liver disease has been constrained by the inability to expand primary hepatocytes vitro while maintaining proliferative capacity and metabolic function. We others have previously shown that mouse mature can be converted progenitor-like cells with defined chemical factors. Here we describe a protocol achieving efficient conversion into (HepLPCs) through delivery developmentally relevant cues, including NAD + -dependent deacetylase SIRT1...
Sorafenib, an orally available kinase inhibitor, is the standard first-line systemic drug for advanced hepatocellular carcinoma (HCC), and it exerts potent inhibitory activity against epithelial–mesenchymal transition (EMT) multidrug resistance (MDR) by inhibiting mitogen-activated protein (MAPK) signaling in HCC. However, after long-term exposure to sorafenib, HCC cells exhibit EMT sorafenib. The activation of AKT sorafenib thought be responsible development these characteristics. present...
This study investigated the contribution of survivin and its upstream regulators, AKT hypoxia‐inducible factor 1α ( HIF –1α), to resistance gastric cancer cells cisplatin CDDP ). We found that over‐expression increased SGC 7901 BGC 823 . Its abrogated ‐induced inhibition cell proliferation apoptosis. In contrast, down‐regulation expression using small hairpin RNA (sh ) vectors small‐molecule inhibitor YM 155, or function a recombinant cell‐permeable dominant‐negative protein (d NS ur9),...
Sorafenib resistance remains a major obstacle for the effective treatment of hepatocellular carcinoma (HCC), and number miRNAs contribute to this resistance. However, regulatory networks are very complex, thus inhibiting single miRNA may sequentially activate other compensatory pathways. In present study, we generated an artificial long non-coding RNA (AlncRNA), which simultaneously targets multiple including miR-21, miR-153, miR-216a, miR-217, miR-494 miR-10a-5p. These have been shown be...